• 1
    Danesh J & Pounder RE. Eradication of Helicobacter pylori and non-ulcer dyspepsia. Lancet 2000; 355: 7667.
  • 2
    Talley NJ, Axon A, Bytzer P, Holtmann G, Lam SK, Veldhuyzen van Zanten S. Management of uninvestigated and functional dyspepsia: a working party report for the World Congress of Gastroenterology 1998. Aliment Pharmacol Ther 1999; 13: 113548.DOI: 10.1046/j.1365-2036.1999.00584.x
  • 3
    Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GNJ. Functional gastrointestinal disorders. Gut 1999; 45(Suppl. II): 113742.
  • 4
    Fisher RS & Parkman HP. Management of non ulcer dyspepsia. New Engl J Med 1998; 339: 137681.
  • 5
    Stanghellini V, Tosetti C, Barbara G, De Giorgio R, Salvioli B, Corinaldesi R. Review article: the continuing dilemna of dyspepsia. Aliment Pharmacol Ther 2000; 14(Suppl. 3): 2330.DOI: 10.1046/j.1365-2036.2000.00684.x
  • 6
    Bruley des Varannes S & Scarpignato C. Relations entre gastrite àHelicobacter pylori et symptomatologie clinique. Gastroenterol Clin Biol 1996; 20: 8393.
  • 7
    Talley NJ. A critique of therapeutic trials in Helicobacter pylori-positive functional dyspepsia. Gastroenterology 1994; 106: 117483.
  • 8
    Malfertheiner P, Megraud F, O'Morain C, et al.Current European concepts in the management of Helicobacter pylori infection—The Maastricht Consensus report. Eur J Gastroenterol Hepatol 1997; 9: 12.
  • 9
    Lam SK & Talley NJ. Report of the 1997 Asia Pacific consensus guidelines on the management of H pylori. J Gastroenterol Hepatol 1998; 13: 112.
  • 10
    Talley NJ, Janssens J, Lauritsen K, Racz I, Bolling-Sternevald E. Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months’ follow up. Br Med J 1999; 318: 8337.
  • 11
    Talley NJ, Vakil N, Ballard ED, Fennerty MB. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. New Engl J Med 1999; 341: 110611.
  • 12
    Blum AL, Talley NJ, O'Morain C, et al.Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. New Engl J Med 1998; 339: 187581.
  • 13
    McColl K, Munay L, El-Omar E, et al.Symptomatic benefit from eradicating Helicobacter pylori infection in patients with non ulcer dyspepsia. New Engl J Med 1998; 339: 186974.
  • 14
    Bruley des Varannes S, Flejou JF, Colin R, Zaim M, Meunier A. Helicobacter pylori eradication in non-ulcer dyspepsia: a randomized, double blind, placebo-controlled study with a 12-month follow-up. Gastroenterology 2000; 118: A468A468(Abstract).
  • 15
    Moayyedi P, Soo S, Deeks J, et al.Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Br Med J 2000; 321: 65964.
  • 16
    Fléjou JF. Diagnostic anatomo-pathologique de l’infection àHelicobacter pylori. In: Mégraud F, Lamouliatte H, eds. Helicobacter pylori. Paris: Elsevier, 1996: 235–47.
  • 17
    Dixon MF, Genta RM, Yardley JH, et al.Classification and grading of gastritis. The updated Sydney system. Am J Surg Pathol 1996; 20: 116181.
  • 18
    Ware J, Kosinski M, Keller S. SF-36 Physical and Mental Health Summary Scales; a User’s Manual, 2nd edn. Boston: Mass, The health Institute, New England Medical Center, 1994.
  • 19
    Finney JS, Kinnersley N, Hugues M, et al.Meta-analysis of antisecretory and gastrokinetic compounds in functional dyspepsia. J Clin Gastroenterol 1998; 26: 31220.
  • 20
    Veldhuyzen van Zanten S, Cleary C, Talley NJ, et al.Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for the design of future trials. Report of an international working party. Am J Gastroenterol 1996; 91: 66073.
  • 21
    Veldhuyzen van Zanten SJO, Talley NJ, Bytzer P, Klein KB, Whorwell PJ, Zinsmeister AR. Design of treatment trials for functional gastrointestinal disorders. Gut 1999; 45(Suppl. II): 116977.
  • 22
    Bigard MA, Delchier JC, Riachi G, Thibault P, Barthelemy P. One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of H. pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin. Aliment Pharmacol Ther 1998; 12: 3838.DOI: 10.1046/j.1365-2036.1998.00315.x
  • 23
    Ruszniewski P, Lamouliatte H, Fléjou JF, Mégraud F, Slama A. Evaluation of short-term ranitidine versus omeprazole triple therapy regimens for eradication of H. pylori in duodenal ulcer patients. Gut 1997; 41(Suppl. 1): A94A94(Abstract).
  • 24
    Lamouliatte H, De Mascarel A, Mégraud F, Samoyeau R. Double-blind study comparing once daily versus twice daily dosage of PPI with amoxycillin, clarithromycin for H. pylori cure. Gut 1997; 41(Suppl. 1): A93A93(Abstract).
  • 25
    Broutet N, Tchamgoue S, Pereira E, Lamouliatte H, Mégraud F. Factors associated with anti-Helicobacter pylori triple therapies outcome—Results from of a cohort of 1214 patients in France. Gastroenterology 2000; 118: A1219A1219(Abstract).
  • 26
    Genta RM. A year in the life of gastric mucosa. Gastroenterology 2000; 119: 2524.
  • 27
    Sung JJY, Lin SR, Ching JYL, et al.Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 2000; 119: 714.
  • 28
    Schenk BE, Kuipers EJ, Nelis GF, et al.Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut 2000; 46: 61521.